Compound Manufacturing Company Development Phase
T-1095 Tanabe Discontinued
TS-033 Taisho Discontinued
AVE2268 Sanofi-Aventis Discontinued
YM-543 Astellas/Kotobuki Discontinued
Remogliflozin GlaxoSmithKline Discontinued
Sergliflozin GlaxoSmithKline/Kissei Discontinued
Dapagliflozin Bristol-Myers Squibb/AstraZeneca Phase III
Canagliflozin JNJ/Mitsubishi Tanabe Phase III
BI 10773 BoehringerIngelheim Phase II
BI 44847 BoehringerIngelheim/Ajinomoto Phase II
R-7201 Roche/Chugai Phase II
TS-071 Taisho Phase II
LX4211 Lexicon Phase II
Table 5: Clinical progress of some important SGLT2 inhibitors for the treatment of type 2 diabetes mellitus [39].